Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isotechnika Pharma has entered a Global Development and Commercialization License agreement with Vifor Pharma.
Subscribe to our email newsletter
As per the agreement Vifor Pharma is granted an exclusive license for the Isotechnika’s drug, voclosporin, to treat lupus and all proteinuric nephrology indications (the Vifor Pharma License).
The Vifor Pharma License is for the US and other regions outside of Canada, South Africa, Israel, China, Taiwan and Hong Kong (the Vifor Pharma Territory).
Isotechnika will receive upfront and milestone payments, as well as royalties on commercial sales.
In addition, Vifor Pharma will also be purchasing voclosporin capsules from Isotechnika, as part of the agreement.